Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 11,333 matching trials from the live ClinicalTrials.gov search.

Filters: Cleveland, Ohio Clear all

Conditions: Tibial Nonunions
Interventions: Surgical implantation of OP-1 device or autograft bone graft material; Device
Lead sponsor: Olympus Biotech Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 18
States / cities: Mesa, Arizona • Modesto, California • San Diego, California + 15 more

Conditions: Arthritis
Interventions: 3D imaging & surrogate bone model; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Parkinson's Disease, Idiopathic
Interventions: Methylphenidate, Physical Therapy, Atomoxetine; Drug · Other
Lead sponsor: Hubert Fernandez; Other
Eligibility: 18 Years to 90 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: SI Joint Pain
Interventions: 0.75% bupivacaine, .75% bupivacaine; Drug
Lead sponsor: SI-BONE, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Mount Vernon, Illinois • Lexington, Kentucky • Cleveland, Ohio + 4 more

Conditions: Aspirin Sensitivity
Interventions: Omalizumab, placebo; Drug
Lead sponsor: David Lang; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions: Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Breast Cancer
Interventions: Cyclophosphamide, Docetaxel, Doxorubicin, Tamoxifen; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: Female only
Enrollment: 2,411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2010
U.S. locations: 134
States / cities: Huntsville, Alabama • Phoenix, Arizona • Greenbrae, California + 115 more

Conditions: Lung; Node
Interventions: RAB via the Monarch platform, RAB via the ION platform; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stroke, Multiple Sclerosis, Rheumatoid Arthritis
Interventions: SystemCHANGE Group Lifestyle counseling, Phone Lifestyle Counseling; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: BSP Biological Signal Processing Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Cleveland, Ohio • Charlottesville, Virginia

Conditions: Hodgkin Lymphoma
Interventions: favezelimab/pembrolizumab, bendamustine, gemcitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 16
States / cities: Tucson, Arizona • Los Angeles, California • Torrance, California + 10 more

Conditions: B-Cell Malignancies
Interventions: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Hypertension in Pregnancy, Obstetrical Complications
Interventions: Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 14 Years to 56 Years · Female only
Enrollment: 4,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Staphylococcal Vaccine
Interventions: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 3,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 234
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more

Conditions: Colitis, Ulcerative
Interventions: Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more

Conditions: Foregut Neuroendocrine Tumor, Hindgut Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Neuroendocrine Tumor, Midgut Neuroendocrine Tumor G1, Neuroendocrine Tumor G2, Recurrent Digestive System Neuroendocrine Tumor G1, Regional Digestive System Neuroendocrine Tumor G1
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pazopanib Hydrochloride, Placebo Administration, Quality-of-Life Assessment, X-Ray Imaging; Procedure · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 412
States / cities: Anchorage, Alaska • Scottsdale, Arizona • Anaheim, California + 263 more

Conditions: HIV-1 Infection
Interventions: Sitagliptin, Placebo for sitagliptin; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 16
States / cities: Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 11 more

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Chronic Thromboembolic Pulmonary Hypertension
Interventions: Selexipag, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 32
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Physician's Choice medications; Drug
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more

Conditions: Mitral Regurgitation, Mitral Valve Insufficiency
Interventions: SAPIEN M3 valve and dock; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 786 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 44
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 36 more

Conditions: Cervical Cancer
Interventions: cisplatin, vincristine sulfate, surgical procedure, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Bellflower, California • Los Angeles, California + 35 more

Conditions: Ascites, Variceal Bleeding, Portal Hypertension Related to Cirrhosis
Interventions: GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm); Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia • Minneapolis, Minnesota • Cleveland, Ohio

Conditions: Candidiasis, Candidemia
Interventions: voriconazole (Vfend); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 14
States / cities: Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more

Search by objective public record fields.

OP Device vs. Bone Autograft for the Treatment of Tibial Nonunions

Real Time 3D Imaging and Surrogate Bone Model

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

Validity and Reliability of Diagnostic Findings of SI Joint Blocking

Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

Abbott Structural Heart Device Registry

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Robotic Systems Evaluation for Peripheral Pulmonary Lesions (RISE Trial)

Health Promotion and Wellness Program for Adults With Disabling Conditions

Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Sitagliptin for Reducing Inflammation and Immune Activation

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

The ENCIRCLE Trial

Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer

VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection